Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1716-1724

  Rink, Michael ^a,b   Park, Kyung ^a   Volkmer, Björn G ^c   Xylinas, Evanguelos ^a,d   Hansen, Jens ^b   Cha, Eugene K ^a   Robinson, Brian D ^a   Hautmann, Richard ^e   Küfer, Rainer ^f   Engel, Oliver ^b   Chun, Felix K ^b   Dahlem, Roland ^b   Rubin, Mark A ^a   Shariat, Shahrokh F ^a   Mosquera, Juan Miguel ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Hospital Kassel   (Germany)

^d Institut Cochin   (France)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f Hospital Am Eichert   (Germany)

Author keywords

Outcome; Radical cystectomy; Serine peptidase inhibitor Kazal type 1 (SPINK1); Survival; Tumor associated trypsin inhibitor (TATI); Urothelial carcinoma

Indexed keywords

PROTEIN; SERINE PROTEASE INHIBITOR KAZAL TYPE I PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; CYSTECTOMY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RECURRENCE RISK; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

OUTCOME; RADICAL CYSTECTOMY; SERINE PEPTIDASE INHIBITOR KAZAL TYPE-1 (SPINK1); SURVIVAL; TUMOR-ASSOCIATED TRYPSIN INHIBITOR (TATI); UROTHELIAL CARCINOMA;

AGED; CARCINOMA, TRANSITIONAL CELL; CARRIER PROTEINS; CYSTECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84886286560     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.06.011     Document Type: Article

References (25)

1. Siegel R., Ward E., Brawley O., et al. Cancer statistics 2011. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-362.
2. Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003, 21:690-696.
3. Shariat S.F., Karakiewicz P.I., Palapattu G.S., et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: A contemporary series from the bladder cancer Research Consortium. J Urol 2006, 176:2414-2422. Discussion 22.
4. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
5. Rink M., Cha E.K., Green D., et al. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep 2012, 13:122-135.
6. Matsushita K., Cha E.K., Matsumoto K., et al. Immunohistochemical biomarkers for bladder cancer prognosis. Int J Urol 2011, 18:616-629.
7. Putluri N., Shojaie A., Vasu V.T., et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res 2011, 71:7376-7386.
8. Lotan Y., Shariat S.F., Schmitz-Dräger B.J., et al. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol 2010, 28:441-448.
9. Shariat S.F., Lotan Y., Vickers A., et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 2010, 28:389-400.
10. Wang G.P., Xu C.S. Pancreatic secretory trypsin inhibitor: More than a trypsin inhibitor. World J Gastrointest Pathophysiol 2010, 1:85-90.
11. Kazal L.A., Spicer D.S., Brahinsky R.A. Isolation of a crystalline trypsin inhibitor-anticoagulant protein from pancreas. J Am Chem Soc 1948, 70:3034-3040.
12. Shibata T., Ogawa M., Takata N., et al. Distribution of pancreatic secretory trypsin inhibitor in various human tissues and its inactivation in the gastric mucosa. Res Commun Chem Pathol Pharmacol 1987, 55:243-248.
13. Gaber A., Johansson M., Stenman U.H., et al. High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. Br J Cancer 2009, 100:1540-1548.
14. Ozaki N., Ohmuraya M., Hirota M., et al. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol Cancer Res 2009, 7:1572-1581.
15. Paju A., Vartiainen J., Haglund C., et al. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: Prognostic study on tissue and serum. Clin Cancer Res 2004, 10:4761-4768.
16. Stenman U.H. Tumor-associated trypsin inhibitor. Clin Chem 2002, 48:1206-1209.
17. Tomlins S.A., Rhodes D.R., Yu J., et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008, 13:519-528.
18. Patschan O., Shariat S.F., Chade D.C., et al. Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder. World J Urol 2011 Jul 8, [Epub ahead of print].
19. Eble J.N., Sauter G., Epstein J.I., et al. World Health Organization classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs 2004, IARCC Press, Lyon.
20. American Joint Committee on Cancer (AJCC) Cancer Staging Manual 2002, Springer-Verlag, New York, New York. 6th ed.
21. Hotakainen K., Bjartell A., Sankila A., et al. Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. Int J Oncol 2006, 28:95-101.
22. Wiksten J.P., Lundin J., Nordling S., et al. High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favorable prognosis in gastric cancer. Histopathology 2005, 46:380-388.
23. Shariat S.F., Palapattu G.S., Karakiewicz P.I., et al. Discrepancy between clinical and pathologic stage: Impact on prognosis after radical cystectomy. Eur Urol 2007, 51:137-149. Discussion 49-51.
24. Svatek R.S., Shariat S.F., Novara G., et al. Discrepancy between clinical and pathological stage: External validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 2011, 107:898-904.
25. Shariat S.F., Herman M.P., Casella R., et al. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol 2005, 48:424-431.